BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35777267)

  • 21. HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer.
    Deng R; Zhang P; Liu W; Zeng X; Ma X; Shi L; Wang T; Yin Y; Chang W; Zhang P; Wang G; Tao K
    Clin Epigenetics; 2018 Dec; 10(1):153. PubMed ID: 30537988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
    Tanizaki J; Okamoto I; Takezawa K; Tsukioka S; Uchida J; Kiniwa M; Fukuoka M; Nakagawa K
    Mol Cancer Ther; 2010 May; 9(5):1198-207. PubMed ID: 20424000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B7-H3-targeted CAR-T cell therapy for solid tumors.
    Li G; Wang H; Wu H; Chen J
    Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.
    Mao Y; Li W; Chen K; Xie Y; Liu Q; Yao M; Duan W; Zhou X; Liang R; Tao M
    Oncotarget; 2015 Feb; 6(5):3452-61. PubMed ID: 25609202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer.
    Castagnoli L; Corso S; Franceschini A; Raimondi A; Bellomo SE; Dugo M; Morano F; Prisciandaro M; Brich S; Belfiore A; Vingiani A; Di Bartolomeo M; Pruneri G; Tagliabue E; Giordano S; Pietrantonio F; Pupa SM
    Cell Oncol (Dordr); 2023 Jun; 46(3):661-676. PubMed ID: 36753044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers.
    Rao Y; Samuels Z; Carter LM; Monette S; Panikar SS; Pereira PMR; Lewis JS
    Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2220413120. PubMed ID: 36972439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer.
    Li ZY; Wang JT; Chen G; Shan ZG; Wang TT; Shen Y; Chen J; Yan ZB; Peng LS; Mao FY; Teng YS; Liu JS; Zhou YY; Zhao YL; Zhuang Y
    Clin Immunol; 2021 Jun; 227():108753. PubMed ID: 33945871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B7-H3, Negatively Regulated by miR-128, Promotes Colorectal Cancer Cell Proliferation and Migration.
    Hu X; Xu M; Hu Y; Li N; Zhou L
    Cell Biochem Biophys; 2021 Jun; 79(2):397-405. PubMed ID: 33743142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment.
    Kwon HJ; Park Y; Nam SK; Kang E; Kim KK; Jeong I; Kwak Y; Yoon J; Kim TY; Lee KW; Oh DY; Im SA; Kong SH; Park DJ; Lee HJ; Kim HH; Yang HK; Lee HS
    Cancer Med; 2023 May; 12(9):10371-10384. PubMed ID: 36916290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-199a Inhibits Cell Proliferation, Migration, and Invasion and Activates AKT/mTOR Signaling Pathway by Targeting B7-H3 in Cervical Cancer.
    Yang X; Feng KX; Li H; Wang L; Xia H
    Technol Cancer Res Treat; 2020; 19():1533033820942245. PubMed ID: 32856542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anchoring of hyaluronan glycocalyx to CD44 reduces sensitivity of HER2-positive gastric cancer cells to trastuzumab.
    Chen S; Zhang G; Liu Y; Yang C; He Y; Guo Q; Du Y; Gao F
    FEBS J; 2024 Apr; 291(8):1719-1731. PubMed ID: 38275079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
    Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
    Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity.
    Zhang W; Wang Y; Wang J; Dong F; Zhu M; Wan W; Li H; Wu F; Yan X; Ke X
    Int J Oncol; 2015; 46(6):2562-72. PubMed ID: 25872657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis.
    Wang HB; Liao XF; Zhang J
    Medicine (Baltimore); 2017 Nov; 96(44):e8437. PubMed ID: 29095284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastric Carcinomas with Stromal B7-H3 Expression Have Lower Intratumoural CD8+ T Cell Density.
    Ulase D; Behrens HM; Krüger S; Zeissig S; Röcken C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer.
    Ko BK; Lee SY; Lee YH; Hwang IS; Persson H; Rockberg J; Borrebaeck C; Park D; Kim KT; Uhlen M; Lee JS
    Mol Oncol; 2015 Feb; 9(2):398-408. PubMed ID: 25306393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function.
    Yue J; Shao S; Zhou J; Luo W; Xu Y; Zhang Q; Jiang J; Zhu MM
    Invest New Drugs; 2024 Feb; 42(1):106-115. PubMed ID: 38198061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo.
    Shu M; Yan H; Xu C; Wu Y; Chi Z; Nian W; He Z; Xiao J; Wei H; Zhou Q; Zhou JX
    Sci Rep; 2020 Feb; 10(1):2986. PubMed ID: 32076029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.